Summary
Angiogenesis is essential for tumor growth and metastases. Studies in breast carcinomas suggest that microvessel quantitation as a measure of angiogenesis might be one of the most powerful prognostic tools available. Node negative breast cancer is a particular group for which better prognostic markers would be helpful. We therefore measured microvessel density in a series of well characterised node negative breast carcinomas to evaluate angiogenesis as a prognostic marker and assess its relationship to epidermal growth factor receptor (EGFR) and estrogen receptor (ER), which have previously been reported to be of value. 109 patients with a mean age of 55 years and a median follow-up of 25 months were examined. Vessels were immunohistochemically highlighted using an antibody to platelet endothelial cell adhesion molecule CD31, and microvessel density was quantified using a Chalkley point eyepiece graticule. No significant correlation was observed with patient age, tumor size, grade, ER, or EGFR expression. In a univariate analysis of survival, whereas ER expression was not a significant indicator of either relapse-free (RFS) or overall survival (OS), vascular count (VC) predicted both early RFS and OS (p=0.01 and p=0.028 respectively). Furthermore, in patients with ER positive tumors, a subgroup usually considered to have a good prognosis, there was a significant reduction in RFS and OS if tumors had high VCs (p=0.05 and p=0.002 respectively). A further statistically significant reduction in RFS (p=0.05) was observed for EGFR positive highly vascular tumors. In a Cox proportional hazard model, VC remained a significant prognostic indicator for both RFS and OS (p=0.04 and p=0.01) and conferred a 6.6 and 3.5 times respective increased risk of mortality and relapse. These findings suggest that quantitation of angiogenesis is an independent predictor of survival in node negative breast carcinomas, and due to these high hazard ratios might be more useful than other recently described prognostic markers in selecting patients who would benefit from adjuvant therapy.
References
Folkman J: What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82:4–6, 1990
Rice G, Bevilacqua M: An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 246:1303–1306, 1988
Horak E, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 340:1120–1124, 1992
Bosari S, Lee A, DeLellis R, Wiley B, Heatley G, Silverman M: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761, 1992
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med 324:1–8, 1991
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred E, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992
Gasparini G, Pozza F, Harris A: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206–1219, 1993
The Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of peri-operative adjuvant chemotherapy for node negative breast cancer. N Engl J Med 320:491–496, 1980
Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146–150, 1991
Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77–90, 1989
Silvestrini R, Benini E, Daidone M, Veneroni S, Boracchi P, Capelletti V, di Fronzo G, Veronesi U: p53 as an independent prognostic marker in node negative breast cancer patients. J Natl Cancer Inst 85:965–970, 1993
Elston C: Grading of invasive carcinoma of the breast.In: Page D, Anderson T (eds) Diagnostic Histopathology of the Breast. Churchill Livingstone, Edinburgh, 1987, pp 300–311
Needham GK, Nicholson S, Angus B, Farndon JR, Harris AL: Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res 48:6603–6607, 1988
Parums D, Cordell J, Micklem K, Heryet A, Gatter K, Mason D: JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752–757, 1990
McCarthy SA, Kuzu I, Gatter KC, Bicknell R: Heterogeneity of the endothelial cell and its role in organ preference of tumour metastasis. Trends Pharmacol Sci 12:462–467, 1991
Kuzu I, Bicknell R, Harris AL, Jones M, Gatter KC, Mason DY: Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol 45:143–412, 1992
Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398–402, 1987
Goldman C, Kim J, Wong W-L, King V, Brock T, Gillespie G: Epidermal growth factor stimulates vascular endothelial cell growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121–133, 1993
Schreiber AB, Winkler ME, Derynck R: Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250–1253, 1986
Allred D, Clark G, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer. J Natl Cancer Inst 85:200–206, 1993
Ciocca D, Clark G, Tandon A, Fuqua S, Welch W, McGuire W: Heat shock protein hsp 70 in patients with axillary lymph node negative breast cancer: prognostic implications. J Natl Cancer Inst 85:570–574, 1993
Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Janicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101–6105, 1992
Kute TE, Shao Z-M, Sugg NK, Long RT, Russell G, Case LD: Cathepsin D as a prognostic indicator for node negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52:5198–5203, 1992
Fox SB, Hollyer J, Smith K, Greenall M, Hastrich D, Harris AL: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29:41–49, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fox, S.B., Leek, R.D., Smith, K. et al. Tumor angiogenesis in node-negative breast carcinomas — relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Tr 29, 109–116 (1994). https://doi.org/10.1007/BF00666186
Issue Date:
DOI: https://doi.org/10.1007/BF00666186